This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months



Status:Recruiting
Conditions:Schizophrenia
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 55
Updated:4/5/2019
Start Date:December 7, 2017
End Date:December 31, 2020
Contact:Boehringer Ingelheim
Email:clintriage.rdg@boehringer-ingelheim.com
Phone:1-800-243-0127

Use our guide to learn which trials are right for you!

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia.

The objective of the study is to investigate the efficacy, safety and tolerability of BI
409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on
antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo
in preventing relapse of schizophrenia symptoms.


Inclusion Criteria:

- International Statistical Classification of Diseases and Related Health Problems, 10th
Revision (ICD-10) diagnosis of schizophrenia >= one year prior to randomisation.

- Outpatients in the stable phase of illness, as assessed by the investigator after
review of medical records or documented discussion with treating clinician.

- Patients currently taking a stable dose of antipsychotic medication(s) for at least 12
weeks prior to randomisation.

- Detectable level of current antipsychotic medication(s) in plasma from blood drawn at
Visit 1 (unless no assay is available for the antipsychotic(s) currently prescribed).

- Patients who have experienced at least 2 relapses within the past 5 years or at least
1 relapse if they were diagnosed less than 3 years ago. Relapse is defined as the
patient having any of the following using the above number of relapses and time
frames:

- Hospitalization for psychosis (involuntary or voluntary admission), intensive
outpatient therapy or use of home treatment as an alternative to hospitalization
(verified via medical record).

- Emergency Department visit for worsening schizophrenia symptoms (verified via
medical record).

- Deliberate self-injury and/or violent behaviour resulting in significant injury
to another person or property (verified by police record or treating mental
health provider written record or documented phone conversation).

- Change in the patient's antipsychotic medication or increase in antipsychotic
medication dosage due to worsening of schizophrenia symptoms (verified by
pharmacy records or treating mental health provider written record or documented
phone conversation).

- Clinical Global Impressions-Severity (CGI-S) score ≤4 at Visit 1 and 2.

- Positive and Negative Syndrome Scale (PANSS) total score <80 and a score of ≤ 4 on
individual PANSS items conceptual disorganization, hallucinatory behavior,
suspiciousness, and unusual thought content at Visit 1.

- Of full age (according to local legislation, usually ≥ 18 years) and ≤ 55 years at the
time of informed consent.

- Patients must have an identified informant who will be consistent throughout the
study.

- Patients who report living at the same address for the 3 months prior to
randomisation.

- Male or female patients.

-- Female patients of childbearing potential must be ready and able to use highly
effective methods of birth control per International Conference on Harmonisation (ICH)
M3 (R2) that result in a low failure rate of less than 1% per year when used
consistently and correctly. Patients must agree to use birth control throughout the
trial and for at least 28 days after treatment has ended. Acceptable methods of birth
control include combined estrogen-progestin oral, intravaginal or transdermal
contraceptives, progestogen-only oral, injectable or implantable contraceptives,
intrauterine devices (IUDs), intrauterine hormone releasing systems (IUSs), bilateral
tubal occlusion, vasectomized sexual partner, and complete sexual abstinence (if
acceptable by local health authorities) is allowed when this is in line with the
preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar,
ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable
methods of contraception.

- Male patients who are able to father a child must be ready and able to be abstinent or
use adequate contraception for the duration of study participation and for at least 28
days after treatment has ended.

- Signed and dated written informed consent in accordance with International Conference
on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to
admission to the trial. If the patient has a legal representative, then this legal
representative must give written informed consent as well.

Exclusion criteria:

- Patients treated with more than two antipsychotic medications (including more than two
dosage forms).

- Patients who are currently being treated with clozapine, or who have been treated with
clozapine in the past 5 years.

- Patients with a categorical diagnosis of another current major psychiatric disorder
per the Mini-international neuropsychiatric Interview (M.I.N.I.).

- Homicidal behaviour (in the investigator's judgement) in the past 2 years.

- Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,
aborted attempt, or preparatory acts or behavior).

- Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale
(CSSRS) in the past 3 months (i.e. active suicidal thought with intent but without
specific plan, or active suicidal thought with plan and intent).

- In the judgment of the investigator, any clinically significant finding from the
physical examination or laboratory value deviating from normal or any evidence of a
clinically significant concomitant disease or any other clinical condition that would
jeopardize a patient's safety while participating in the clinical trial.

- Other known neurological diseases (including but not limited to any kind of seizures
or stroke).

- Any documented active or suspected malignancy or history of malignancy within 5 years
prior to screening, except appropriately treated basal cell carcinoma of the skin or
in situ carcinoma of uterine cervix.

- Planned elective surgery requiring general anesthesia, or hospitalization for more
than 1 day during the study period.

- Significant history of drug or alcohol dependence or abuse (Substance Use Disorder as
defined in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
or ICD-10) within the last six months prior to informed consent. (Not including
caffeine or nicotine).

- Patients who must or wish to continue the intake of restricted medications or any drug
considered likely to interfere with the safe conduct of the trial.

- Patients taking strong or moderate CYP1A2 inhibitors who are also a CYP2C19 Poor
Metabolizer (PM). Patients taking medication known to be strong or moderate inhibitors
of CYP1A2 must be prospectively genotyped to ensure they are not poor metabolizers of
CYP2C19. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the Investigator
Site File (ISF)).

- Patients taking strong or moderate CYP1A2 inhibitors who are also taking concomitant
strong or moderate CYP2C19 inhibitors. (A list of CYP1A2 and CYP2C19 inhibitors can be
found in the ISF)

- Patients with a history of moderate to severe hepatic impairment (Child-Pugh B / C).

- Patients with a history of moderate to severe renal impairment (Stage 3 - 5).

- Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

- In the judgment of the investigator, inability of the patient to comply with the
clinical trial procedures.

- Currently enrolled in another investigational device or drug study, or less than 6
months from Visit 1 since ending another investigational device or drug study(s), or
participation in > 2 investigational drug clinical trials in the past 2 years.

- Previous randomisation in any BI 409306 study.
We found this trial at
28
sites
North Miami, Florida 33021
Phone: +001 (305) 722-8444-x2248
?
mi
from
North Miami, FL
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Phone: +001 (310) 268-3647
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
Phone: +001 (305) 243-4094
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Ann Arbor, Michigan 48105
Phone: +001 (734) 834-8954
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30331
Phone: +001 (404) 881-5800
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas 78754
Phone: +001 (512) 323-2622
?
mi
from
Austin, TX
Click here to add this to my saved trials
Berlin, New Jersey
Phone: +001 (856) 753-7335-x350
?
mi
from
Berlin, NJ
Click here to add this to my saved trials
Calgary, Alberta
Phone: 403 210-6899
?
mi
from
Calgary,
Click here to add this to my saved trials
Cedarhurst, New York 11516
Phone: +001 (516) 295-7230
?
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Chicago, Illinois 60612
Phone: +001 (630) 928-1000
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Costa Mesa, California 92626
Phone: +001 (714) 277-4472
?
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Flowood, Mississippi 39232
Phone: +001 (601) 420-5810
?
mi
from
Flowood, MS
Click here to add this to my saved trials
12772 Valley View Street
Garden Grove, California 92845
Phone: +001 (714) 799-7799
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Glendale, California 91204
Phone: +001 (888) 255-5798
?
mi
from
Glendale, CA
Click here to add this to my saved trials
Hialeah, Florida 33012
Phone: +001 (786) 536-4177
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Irving, Texas 75062
Phone: +001 (972) 717-6262
?
mi
from
Irving, TX
Click here to add this to my saved trials
Lake Charles, Louisiana 70601
Phone: +001 (337) 564-6405
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Las Vegas, Nevada 89102
Phone: +001 (602) 562-7000
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lemon Grove, California 91945
Phone: +001 (619) 303-6130
?
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
Maitland, Florida 32751
Phone: +001 (407) 644-1165
?
mi
from
Maitland, FL
Click here to add this to my saved trials
1051 Riverside Dr
New York, New York 10032
646-774-5000
Phone: +001 (646) 774-6738
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oceanside, California 92056
Phone: +001 (760) 758-2222
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
1010 West Chapman Avenue
Orange, California 92868
Phone: +001 (714) 289-1100
?
mi
from
Orange, CA
Click here to add this to my saved trials
2300 Maitland Center Parkway
Orlando, Florida 32810
Phone: +001 (407) 644-1165
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Richardson, Texas 75080
Phone: +001 (214) 396-4844
?
mi
from
Richardson, TX
Click here to add this to my saved trials
Saint Charles, Missouri 63301
Phone: +001 (636) 946-8032
?
mi
from
Saint Charles, MO
Click here to add this to my saved trials
5000 Cedar Plaza Parkway
Saint Louis, Missouri 63128
Phone: +001 (314) 849-1853
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
12772 Valley View Street
Torrance, California 90502
Phone: +001 (310) 523-4200
?
mi
from
Torrance, CA
Click here to add this to my saved trials